Multiple Sclerosis
Conditions
Keywords
Ofatumumab, Satisfaction, Patient satisfaction, Physician satisfaction, Relapsing multiple sclerosis
Brief summary
The aim of this study was to assess physician and patient satisfaction with ofatumumab using data collected from physicians and their multiple sclerosis (MS) patients in real-world clinical practice across the United Kingdom (UK), France, Germany, Italy, Spain, China, Japan, and Brazil.
Interventions
None listed
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
Physician inclusion criteria: * Physicians must be actively involved in the treatment/management of patients with MS * Consult with a minimum of 16 MS patients (\>5 in Japan and China, \>10 in Brazil) per month Patient inclusion criteria: Patients for whom physicians complete a Physician Completed Patient Record Form (PRF), and therefore are included in the pool of data for analysis, are based on the following criteria: * Patients who had a physician-made diagnosis of MS before or at the time of data collection * Patients must not currently be involved in a clinical trial * Patients ≥18 years old * For patients included in the ofatumumab sample, they must have been receiving ofatumumab for \>12 months at the time of data collection
Exclusion criteria
• None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number and Percentage of Patients by Patient-reported Level of Satisfaction With Current MS Treatment | 1 Day | Patient's level of satisfaction with current treatment categorized as follows: * Completely dissatisfied * Moderately dissatisfied * Neither dissatisfied nor satisfied * Moderately satisfied * Completely satisfied * Not on any current treatment for MS |
| Number and Percentage of Patients by Patient-reported MS Status With Their Current Medication Compared to Previous Medication | 1 Day | MS status, as reported by the patient, categorized as follows: * Very much better * Much better * A little better * No change * A little worse * Much worse * Very much worse * Don't know * No previous medication taken for MS |
| Number and Percentage of Patients by Physician-reported Patient Response to Current MS Treatment | 1 Day | How well the patient is responding to current treatment rated by the physician from 1 (very poorly) to 5 (very well). |
| Number and Percentage of Patients by Physician-reported Level of Satisfaction With the Patient's Current MS Treatment | 1 Day | Physician's level of satisfaction with patient's current treatment categorized as follows: * Completely dissatisfied * Moderately dissatisfied * Neither dissatisfied nor satisfied * Moderately satisfied * Satisfied * Completely satisfied |
| Number and Percentage of Patients Adherent to Current MS Treatment as Reported by the Physician | 1 Day | Adherence, as reported by the physician, categorized as follows: * Completely adherent * Mostly adherent * Somewhat adherent * A little adherent * Not at all adherent * Too early in patient's regimen to tell * Don't know |
| Number and Percentage of Patients by Physician-reported Change in Patient Condition Since Initiation of Current MS Treatment | 1 Day | Change in condition, as reported by the physician, categorized as follows: * Very much improved * Much improved * A little bit improved * No change * A little bit worse * Much worse * Very much worse |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number and Percentage of Patients by Factors That Influence How the Patient Rates Current Medication Compared to Previous Medication | 1 Day | Factors influencing how patients rate medication include: * Frequency of relapses * Impact on symptoms during relapses * MS progression * Convenience (impact on daily routine) * Side effects * Route of administration * Frequency of administration * Impact on quality of life (e.g. liveliness, social functioning, perceived wellbeing) * No change / No previous medication for MS taken * Don't know |
| Number and Percentage of Patients by Physician-reported Reason for Current MS Treatment Choice | 1 Day | — |
| Number and Percentage of Patients by Physician-reported Top 5 Reasons for Current MS Treatment Choice | 1 Day | — |
| Number and Percentage of Patients by Physician-reported Main Areas of Improvement for the Patient's Current MS Treatment | 1 Day | — |
Countries
Switzerland
Contacts
STUDY_DIRECTORNovartis Pharmaceuticals
Novartis Pharmaceuticals
Outcome results
None listed